NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Measurement of Relaxin Peptide in Multiple Sclerosis (MS)

NCT01909492

CompletedN/A

Sponsor: Providence Health & Services

Conditions: Multiple Sclerosis, Relapsing-Remitting

Interventions: Blood Draw, Lumbar Puncture

Countries: United States

This study will evaluate relaxin (RLX) levels in patients with multiple sclerosis.

Eligibility overview

Sex: FEMALE

Age: 18 Years to 45 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Subjects with suspected MS, who have had a clinical attack within the last 12 weeks, have at least one gadolinium-enhancing lesion on brain or spinal cord MRI taken within the prior 4 weeks, and for which they have not received any immunomodulating or immunosuppressant medication.
* Subjects with clinically stable definite MS, with no evidence of clinical relapse for at least the past 12 weeks, and have no gadolinium enhancing lesions on MRI in the prior 4 weeks. These subjects will fulfill the Revised (2010) McDonald's Criteria for the Diagnosis of MS.
* Subjects without evidence of inflammatory systemic or inflammatory central nervous system disease, who require CSF removal for some other cause, such treatment of benign intracranial hypertension or as part of the procedure for insertion of an intrathecal medication delivery system.

Exclusion Criteria:

\- Pregnancy

Locations (1)

Portland, Oregon, United States